RT Journal Article
SR Electronic
T1 Plasma pharmacokinetics of high dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.11.21250624
DO 10.1101/2021.02.11.21250624
A1 Sean Wasserman
A1 Angharad Davis
A1 Cari Stek
A1 Maxwell Chirehwa
A1 Stephani Botha
A1 Remy Daroowala
A1 Marise Bremer
A1 Mpumi Maxebengula
A1 Sonya Koekemoer
A1 Rene Goliath
A1 Amanda Jackson
A1 Thomas Crede
A1 Jonathan Naude
A1 Patryk Szymanski
A1 Yakoob Vallie
A1 Muhammed S Moosa
A1 Lubbe Wiesner
A1 John Black
A1 Graeme Meintjes
A1 Gary Maartens
A1 Robert J Wilkinson
YR 2021
UL http://medrxiv.org/content/early/2021/02/12/2021.02.11.21250624.abstract
AB Background Higher doses of intravenous rifampicin may improve outcomes in tuberculous meningitis but is impractical in high burden settings. We hypothesized that plasma rifampicin exposures would be similar between oral 35 mg/kg and intravenous 20 mg/kg, which has been proposed for efficacy trials in tuberculous meningitis.Materials and methods We performed a randomized parallel group pharmacokinetic study nested within a clinical trial of intensified antimicrobial therapy for tuberculous meningitis. HIV-positive participants with tuberculous meningitis were recruited from South African hospitals and randomized to one of three rifampicin dosing groups: standard (oral 10 mg/kg), high dose (oral 35 mg/kg), and intravenous (intravenous 20 mg/kg). Intensive pharmacokinetic sampling was done on day 3. Data were described using non-compartmental analysis and exposures compared by geometric mean ratio (GMR).Results Forty-six participants underwent pharmacokinetic sampling (standard dose, n = 17; high dose oral, n= 15; IV, n = 14). Median CD4 count was 130 cells/mm3 (IQR 66 −253). Geometric mean AUC0-∞ was 47.7 µg·h/mL (90% CI, 33.2 – 68.5) for standard dose; 322.3 µg·h/mL (90% CI,234.6 – 442.7) for high dose; and 214.6 µg·h/mL (90% CI, 176.2 – 261.2) for intravenous. High dose oral dosing achieved higher rifampicin exposure than intravenous: AUC0-∞ GMR 0.67 (90% CI, 0.46 −1.0); however, Cmax GMR was 1.11 (90% CI, 0.81 – 1.59), suggesting equivalence.Conclusions Plasma rifampicin exposure was similar with high dose oral and intravenous administration. Findings support oral rifampicin dosing in future tuberculous meningitis trials.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03927313Funding StatementSW was supported by the European & Developing Countries Clinical Trials Partnership (Grant number CDF1018), Wellcome Trust (Grant number 203135/Z/16/Z and 104803), and National Institutes of Health (K43TW011421). AGD is supported through a UCL Wellcome Trust PhD Programme for Clinicians Fellowship (award number 175479). GrM was supported by the Wellcome Trust (098316, 214321/Z/18/Z, and 203135/Z/16/Z), and the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa (Grant No 64787). The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. The opinions, findings and conclusions expressed in this manuscript reflect those of the authors alone. RJW receives support from the Francis Crick Institute which is funded by UKRI (FC0010218). He also receives support from Meningitis Now and NIH (R01AJ145436). Research reported in this publication was also supported by National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (Award nos. UM1 AI068634, UM1 AI068636 and UM1 AI106701).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was conducted in accordance with the Declaration of Helsinki and was approved by the University of Cape Town Human Research Ethics Committee (Ref 293/2018) and the Walter Sisulu University Human Research Committee (Ref 012/2019).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOriginal data available on request